Vaxcyte Appoints John Furey To Board Of Directors
Vaxcyte, Inc. (Nasdaq: PCVX), a vaccine innovation company, announced the appointment of John Furey to its Board of Directors. With over 30 years of biopharmaceutical experience, including key roles in manufacturing, supply, and commercialization of pneumococcal conjugate vaccines, Furey will provide strategic insights as Vaxcyte advances its PCV candidates, VAX-24 and VAX-31, toward late-stage clinical development. CEO Grant Pickering highlighted Furey's expertise as essential for Vaxcyte's ongoing progress.
Furey, currently CEO of Imvax, brings extensive experience from senior positions at Spark Therapeutics, Baxalta, Pfizer, and Wyeth Pharmaceuticals. He expressed enthusiasm for joining Vaxcyte, aiming to leverage the company's cell-free technology platform to develop innovative vaccines addressing bacterial infections. Vaxcyte is focused on creating high-fidelity, broad-spectrum vaccines, including its lead candidate VAX-24 and next-generation VAX-31, to improve the prevention of invasive pneumococcal disease and other serious bacterial infections.
Read More - https://www.techdogs.com/tech-news/globe-newswire/vaxcyte-appoints-john-furey-to-board-of-directors
Comments
Post a Comment